| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...880765C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0080765 |
| P932 | PMC publication ID | 3823618 |
| P698 | PubMed publication ID | 24244714 |
| P5875 | ResearchGate publication ID | 258639754 |
| P2093 | author name string | Norihiro Sato | |
| Shiro Kohi | |||
| Koji Yamaguchi | |||
| Xiao-Bo Cheng | |||
| P2860 | cites work | HYAL1 overexpression is correlated with the malignant behavior of human breast cancer | Q24313097 |
| HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA | Q28137780 | ||
| The hyaluronidase gene HYAL1 maps to chromosome 3p21.2-p21.3 in human and 9F1-F2 in mouse, a conserved candidate tumor suppressor locus | Q28264764 | ||
| Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma | Q29616287 | ||
| Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content | Q33444259 | ||
| HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer | Q33688043 | ||
| The six hyaluronidase-like genes in the human and mouse genomes | Q34103842 | ||
| Hyaluronan catabolism: a new metabolic pathway | Q34361766 | ||
| Localisation of hyaluronate (HA) in primary tumors and nude mouse xenografts of human pancreatic carcinomas using a biotinylated HA-binding protein | Q71659979 | ||
| Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition | Q73098910 | ||
| Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer | Q73693135 | ||
| Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer | Q74093456 | ||
| Signaling properties of hyaluronan receptors | Q34444928 | ||
| Association of hyaluronic acid family members (HAS1, HAS2, and HYAL‐1) with bladder cancer diagnosis and prognosis | Q34512129 | ||
| Mammalian hyaluronan synthases | Q35038976 | ||
| Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival | Q35745456 | ||
| Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. | Q36464111 | ||
| Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer | Q36550798 | ||
| Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate | Q36617504 | ||
| Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression | Q37194824 | ||
| Stromal biology and therapy in pancreatic cancer. | Q37802090 | ||
| Hyaluronan in human malignancies | Q37816562 | ||
| Tumor microenvironment and progression of pancreatic cancer. | Q37852994 | ||
| Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis | Q37858851 | ||
| Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer | Q37885319 | ||
| Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer | Q38021384 | ||
| Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer | Q38452266 | ||
| Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts | Q40507994 | ||
| Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells | Q41169185 | ||
| Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. | Q42818827 | ||
| High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer | Q43582728 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic ductal carcinoma | Q8263002 |
| adenocarcinoma | Q356033 | ||
| P304 | page(s) | e80765 | |
| P577 | publication date | 2013-11-11 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma | |
| P478 | volume | 8 |
| Q50964510 | 3D-spheroids: What can they tell us about pancreatic ductal adenocarcinoma cell phenotype? |
| Q37606733 | 4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells |
| Q54938291 | 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. |
| Q38817997 | A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells |
| Q89972746 | A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma |
| Q42181013 | Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. |
| Q36152259 | Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer |
| Q101120968 | Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer |
| Q38199723 | Brief overview of selected approaches in targeting pancreatic adenocarcinoma |
| Q90140489 | CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach |
| Q91612583 | Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis |
| Q47123105 | Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going |
| Q86521508 | Decreased hyaluronidase 1 expression is associated with early disease recurrence in human endometrial cancer |
| Q89596127 | Direct comparison of optical and electron microscopy methods for structural characterization of extracellular vesicles |
| Q40961838 | ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. |
| Q35653691 | Emerging roles for hyaluronidase in cancer metastasis and therapy |
| Q89967768 | Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy |
| Q26752391 | Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes |
| Q90681590 | Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma |
| Q39997796 | Hyaluronan stimulates pancreatic cancer cell motility |
| Q38930438 | Hyaluronic acid in digestive cancers |
| Q56890107 | Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options |
| Q33764696 | Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance? |
| Q38717187 | KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer |
| Q47701382 | Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. |
| Q93234403 | Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer |
| Q39453620 | Promising therapeutics of gastrointestinal cancers in clinical trials |
| Q38823693 | Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma |
| Q26766075 | Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight |
| Q92259502 | Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer |
| Q33827708 | Stromal reengineering to treat pancreas cancer |
| Q38260975 | Sugars in the microenvironment: the sticky problem of HA turnover in tumors |
| Q38856978 | Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells. |
| Q26752400 | Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma |
| Q37729238 | The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma |
| Q64082778 | The material properties of naked mole-rat hyaluronan |
| Q89586019 | Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer |
Search more.